Coya Therapeutics is a clinical-stage biotechnology company developing therapies to enhance the function of regulatory T cells (Tregs), immune cells that suppress inflammation and maintain cellular balance. The company is advancing three therapeutic modalities—Treg-enhancing biologics (led by a proprietary low-dose interleukin-2 and CTLA4-Ig combination), Treg-derived exosomes, and autologous Treg cell therapy—primarily targeting neurodegenerative and autoimmune diseases where Treg dysfunction drives pathology, including amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and Alzheimer's disease. The company generates no product revenue and is funded through the sale of securities and strategic partnerships, including a collaboration with Dr. Reddy's Laboratories for exclusive licensing rights and milestone-based payments; Coya expects to incur substantial operating losses as it advances candidates through clinical development toward regulatory approval.